Compare Etsy Inc (ETSY) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Etsy Inc vs Recursion Pharmaceuticals Inc — how do they compare? Etsy Inc trades at $85.31 (market cap $8.14B), while Recursion Pharmaceuticals Inc trades at $3.17 (market cap $1.75B). The key difference: Etsy Inc is far larger — about 4.7× Recursion Pharmaceuticals Inc's market cap, and Etsy Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| ETSY | RXRX | |
|---|---|---|
Market Cap | $8.14B | $1.75B |
Sector | Consumer Cyclical | Health |
52-Week High | $85.74 | $6.79 |
52-Week Low | $44.05 | $2.84 |
Enterprise Value | $9.79B | $1.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Etsy stock trades at $83.06, up 3.14% recently and showing strong technical momentum with bullish moving average signals. The company has beaten earnings expectations for three consecutive quarters, with Q1 2026 EPS of $0.89 surpassing the $0.62 estimate. However, valuation metrics appear elevated with a P/E of 32.85 and P/B of 52.12, while the company maintains strong gross margins of 71.55% and positive operating cash flow of $693.41M in 2025.
The outlook is mixed with improving buyer momentum and AI-driven engagement tools supporting growth, but active buyer declines and high debt levels present risks. Analyst sentiment leans positive with 22 buy ratings versus 3 sells, though the consensus price target of $72.38 suggests 13% downside from current levels. The Depop divestiture to eBay removes a distraction, allowing focus on core marketplace improvements.
Recursion Pharmaceuticals (RXRX) trades at $3.175, down 4.94% on the day, reflecting ongoing investor concerns about profitability. The stock shows bearish technical signals with negative moving averages, while fundamentals reveal significant losses with a net income margin of -851.51% despite recent earnings beats. Analyst consensus is mixed with 40% buy ratings but a $7.83 price target suggesting substantial upside potential from current levels.
The outlook remains speculative given the company's heavy losses and cash burn, though AI-driven drug discovery platform and recent clinical progress offer long-term potential. Key risks include prolonged unprofitability, intense biotech competition, and dependence on successful drug development. The stock presents high-risk/high-reward characteristics suitable only for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Etsy Inc
Etsy operates a top-10 e-commerce marketplace operator in the U.S. and the U.K., with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $13.5 billion in 2021 consolidated gross merchandise volume, the firm has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. As of the end of 2021, the firm connected more than 96 million buyers and more than 7.5 million sellers on its marketplace properties: Etsy, Reverb (musical equipment), Elo7 (crafts in Brazil), and Depop (clothing resale).
Read more on ETSY →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
